Miist Therapeutics, founded with a mission to revolutionize addiction treatment, focuses on developing advanced pulmonary drug delivery systems. The company's vision is to significantly reduce the global burden of tobacco-related death and illness. Miist Therapeutics offers a platform inhaler integrated with software controls that personalize medication dosages, currently targeting smoking cessation. Their innovative approach aims to provide more effective and tailored treatments for the over 1.2 billion individuals worldwide struggling with smoking addiction.

Notable figures affiliated with Miist Therapeutics include experts in pulmonary medicine and digital health technologies. The company has attracted significant interest from investors focused on healthcare innovation. Key achievements include the successful development and initial commercialization of their lead inhaled therapy asset. Miist Therapeutics' impact lies in its potential to transform smoking cessation treatments, offering a more personalized and effective solution to a widespread public health issue.